noscript

News and Announcements

SUDA Amends Agreement with Amherst Pharmaceuticals

  • Published December 11, 2015 11:49AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

10th December 2015, ASX Announcement

SUDA Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that it has amended its agreement with Amherst Pharmaceuticals in relation to ZolpiMist for insomnia and SUD-002 for nausea and vomiting.

Under the terms of the new agreement, SUDA has expanded it territorial rights to ZolpiMist to include South America, Central America and South America. As a result, SUDA now has a global license, excluding North America , to this US-registered oral spray of zolpidem tartrate for the treatment of insomnia. As per the cross-licencing agreement signed in January 2015, SUDA will pay Amherst a 6 to 12 per cent share of income from SUDA’s commercialisation of ZolpiMist. Business development discussions with prospective partners are progressing in several countries, including in the expanded territory.

To read the full announcement, please click here

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now